Gene and cell therapies targeting retinal diseases often require delivery to the sub-retinal space to reach their target tissues. Delivery of therapeutics to the subretinal space is currently performed via a short surgical procedure. Through our technology company, Orbit Biomedical, we are developing surgical devices and procedures designed to make delivery of therapeutics to the subretinal space as safe, precise and effective as possible.
Our team brings years of expertise in biomedical engineering, medical device development and clinician training to ophthalmology.
Our goal is to make the administration of one-time therapies as safe and efficient as possible for patients. To achieve this goal, in addition to applying our technology to our own therapeutic programs, we aim to collaborate with partners who are developing therapies to preserve or restore vision in patients suffering from sight-threatening ophthalmic diseases.
To find out more, please click here.